Cesca Therapeutics 7.53M share offering priced at $1.50 Cesca Therapeutics announced the pricing of an underwritten public offering of 7.53M units, consisting of an aggregate of 7.53M shares and warrants to purchase 2.259M shares of the, at a price of $1.50 per unit. The warrants will be exercisable immediately upon issuance at an exercise price of $1.55 per share and will expire five years from the date of issuance. All of the units in the offering are being sold by Cesca. The gross proceeds to Cesca from the offering are expected to be approximately $11.3M. The offering is expected to close on or about June 18. Maxim Group is acting as sole book-running manager and H.C. Wainwright & Co. is acting as a co-manager for the offering.
Texas Stem Cell to use Cesca's AutoXpress AXP technology Cesca Therapeutics announced that Texas Stem Cell has committed to utilizing Cesca's AutoXpress AXP technology for its cord blood banking business. The AXP platform includes a 'smart' processing device and sterile disposable that automatically concentrates the stem cells from a cord blood unit in less than one hour and delivers them directly into Cesca's patented sample bag which is optimized for cryopreservation and storage.